Weak sterling boosts GlaxSmithKline as new CEO takes over

LONDON, April 26 (Reuters) - GlaxoSmithKline's new chief executive reported slightly better than expected first-quarter results on Wednesday, keeping the drugmaker on track to hit financial targets in 2017 as it braces for generic competition to blockbuster lung drug Advair.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.